Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Osteosarcoma | 41 | 2024 | 911 | 7.490 |
Why?
|
Bone Neoplasms | 51 | 2025 | 2565 | 5.680 |
Why?
|
Gastrointestinal Stromal Tumors | 16 | 2021 | 617 | 2.700 |
Why?
|
Neuroectodermal Tumors, Primitive, Peripheral | 4 | 2023 | 43 | 2.000 |
Why?
|
Gastrointestinal Neoplasms | 8 | 2021 | 959 | 1.220 |
Why?
|
Neoplasms | 30 | 2024 | 22389 | 1.210 |
Why?
|
High-Throughput Nucleotide Sequencing | 9 | 2024 | 3666 | 1.120 |
Why?
|
Succinate Dehydrogenase | 6 | 2016 | 148 | 1.110 |
Why?
|
Child | 106 | 2025 | 80894 | 1.000 |
Why?
|
Sarcoma | 10 | 2024 | 1806 | 0.940 |
Why?
|
Neoplasm Recurrence, Local | 22 | 2024 | 9433 | 0.910 |
Why?
|
Protein-Tyrosine Kinases | 4 | 2022 | 2433 | 0.890 |
Why?
|
Molecular Targeted Therapy | 13 | 2024 | 2830 | 0.890 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2016 | 640 | 0.880 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 6 | 2019 | 368 | 0.840 |
Why?
|
Fibromatosis, Aggressive | 3 | 2020 | 125 | 0.830 |
Why?
|
Oncogene Proteins, Fusion | 8 | 2023 | 1614 | 0.750 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2021 | 67 | 0.750 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 11854 | 0.710 |
Why?
|
Medical Oncology | 9 | 2023 | 2348 | 0.710 |
Why?
|
Proto-Oncogene Proteins c-kit | 7 | 2019 | 725 | 0.710 |
Why?
|
Ketones | 2 | 2018 | 182 | 0.690 |
Why?
|
Furans | 2 | 2018 | 201 | 0.690 |
Why?
|
Antineoplastic Agents | 12 | 2020 | 13696 | 0.680 |
Why?
|
Adolescent | 70 | 2024 | 89182 | 0.650 |
Why?
|
Paraganglioma | 5 | 2022 | 143 | 0.640 |
Why?
|
Germ-Line Mutation | 11 | 2025 | 1885 | 0.610 |
Why?
|
Receptor, IGF Type 1 | 4 | 2019 | 384 | 0.600 |
Why?
|
Piperazines | 5 | 2024 | 2552 | 0.580 |
Why?
|
Clinical Trials as Topic | 10 | 2024 | 8051 | 0.580 |
Why?
|
Central Nervous System Neoplasms | 2 | 2023 | 930 | 0.570 |
Why?
|
Genomics | 16 | 2024 | 5916 | 0.560 |
Why?
|
Doxorubicin | 7 | 2023 | 2229 | 0.520 |
Why?
|
Child, Preschool | 43 | 2025 | 42654 | 0.520 |
Why?
|
Information Dissemination | 1 | 2024 | 1137 | 0.510 |
Why?
|
Proto-Oncogene Proteins | 4 | 2022 | 4526 | 0.510 |
Why?
|
Soft Tissue Neoplasms | 5 | 2023 | 1166 | 0.500 |
Why?
|
Pediatrics | 5 | 2020 | 3624 | 0.470 |
Why?
|
Ifosfamide | 5 | 2024 | 234 | 0.460 |
Why?
|
Mutation | 22 | 2024 | 30230 | 0.450 |
Why?
|
Gene Fusion | 3 | 2022 | 356 | 0.450 |
Why?
|
Marketing of Health Services | 1 | 2015 | 151 | 0.450 |
Why?
|
Adrenal Gland Neoplasms | 4 | 2022 | 736 | 0.440 |
Why?
|
Protein Kinase Inhibitors | 10 | 2023 | 5707 | 0.430 |
Why?
|
Cyclin-Dependent Kinase 4 | 4 | 2024 | 566 | 0.420 |
Why?
|
Humans | 142 | 2025 | 768298 | 0.420 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2016 | 677 | 0.420 |
Why?
|
Pheochromocytoma | 3 | 2022 | 328 | 0.390 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2024 | 2066 | 0.390 |
Why?
|
Etoposide | 5 | 2024 | 639 | 0.390 |
Why?
|
Sarcoma, Clear Cell | 2 | 2023 | 72 | 0.390 |
Why?
|
Immunoconjugates | 1 | 2019 | 969 | 0.390 |
Why?
|
Ambulatory Care Facilities | 1 | 2017 | 940 | 0.360 |
Why?
|
Young Adult | 38 | 2024 | 60048 | 0.350 |
Why?
|
Cell Respiration | 1 | 2010 | 201 | 0.350 |
Why?
|
Neoadjuvant Therapy | 3 | 2019 | 2909 | 0.340 |
Why?
|
Cyclin-Dependent Kinase 6 | 3 | 2024 | 354 | 0.340 |
Why?
|
Gene Amplification | 3 | 2023 | 1090 | 0.340 |
Why?
|
Infant | 25 | 2024 | 36512 | 0.340 |
Why?
|
DNA Mutational Analysis | 3 | 2016 | 4120 | 0.330 |
Why?
|
Vincristine | 5 | 2024 | 1040 | 0.330 |
Why?
|
Pyrimidines | 3 | 2024 | 3048 | 0.330 |
Why?
|
Lung Neoplasms | 4 | 2023 | 13576 | 0.310 |
Why?
|
Genetic Predisposition to Disease | 8 | 2025 | 18047 | 0.300 |
Why?
|
Prognosis | 19 | 2023 | 30020 | 0.300 |
Why?
|
Tissue Banks | 3 | 2020 | 184 | 0.290 |
Why?
|
Amyloid Precursor Protein Secretases | 2 | 2022 | 614 | 0.280 |
Why?
|
Female | 64 | 2025 | 397050 | 0.280 |
Why?
|
Fibrosarcoma | 2 | 2020 | 313 | 0.280 |
Why?
|
Feasibility Studies | 2 | 2021 | 5311 | 0.280 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2024 | 2884 | 0.270 |
Why?
|
Patient Selection | 2 | 2017 | 4265 | 0.270 |
Why?
|
Proteins | 1 | 2021 | 6006 | 0.270 |
Why?
|
Electron Transport Complex II | 3 | 2019 | 53 | 0.270 |
Why?
|
National Cancer Institute (U.S.) | 6 | 2024 | 300 | 0.270 |
Why?
|
Male | 60 | 2025 | 364870 | 0.270 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4908 | 0.270 |
Why?
|
Pyrroles | 2 | 2024 | 1126 | 0.250 |
Why?
|
Antibodies, Monoclonal | 3 | 2023 | 9261 | 0.230 |
Why?
|
Genomic Structural Variation | 1 | 2025 | 80 | 0.230 |
Why?
|
Adult | 42 | 2025 | 223622 | 0.220 |
Why?
|
Disease-Free Survival | 5 | 2023 | 6856 | 0.220 |
Why?
|
Genetic Testing | 3 | 2017 | 3587 | 0.220 |
Why?
|
Rare Diseases | 2 | 2021 | 630 | 0.220 |
Why?
|
Busulfan | 1 | 2024 | 259 | 0.220 |
Why?
|
Myofibromatosis | 1 | 2023 | 27 | 0.210 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 2 | 2023 | 183 | 0.210 |
Why?
|
Melphalan | 1 | 2024 | 421 | 0.210 |
Why?
|
Internet | 1 | 2015 | 3107 | 0.200 |
Why?
|
Genome, Human | 2 | 2017 | 4450 | 0.200 |
Why?
|
BRCA1 Protein | 3 | 2024 | 1158 | 0.200 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 1906 | 0.200 |
Why?
|
Plasma Cell Granuloma, Pulmonary | 1 | 2021 | 12 | 0.200 |
Why?
|
Cyclophosphamide | 3 | 2024 | 2226 | 0.200 |
Why?
|
Receptor Protein-Tyrosine Kinases | 4 | 2022 | 1628 | 0.200 |
Why?
|
BRCA2 Protein | 2 | 2024 | 802 | 0.190 |
Why?
|
Glomus Tumor | 1 | 2022 | 62 | 0.190 |
Why?
|
Phthalazines | 1 | 2024 | 397 | 0.190 |
Why?
|
Transplantation, Autologous | 2 | 2024 | 2127 | 0.190 |
Why?
|
Rhabdoid Tumor | 1 | 2023 | 211 | 0.190 |
Why?
|
Topotecan | 1 | 2021 | 131 | 0.190 |
Why?
|
Granuloma, Plasma Cell | 1 | 2022 | 80 | 0.190 |
Why?
|
Phenylurea Compounds | 1 | 2024 | 529 | 0.190 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2021 | 43 | 0.190 |
Why?
|
Loss of Heterozygosity | 1 | 2023 | 663 | 0.180 |
Why?
|
Indenes | 1 | 2021 | 59 | 0.180 |
Why?
|
Indoles | 1 | 2009 | 1825 | 0.180 |
Why?
|
Polycythemia | 1 | 2021 | 124 | 0.180 |
Why?
|
Pelvic Neoplasms | 1 | 2022 | 250 | 0.180 |
Why?
|
Tandem Repeat Sequences | 1 | 2021 | 183 | 0.180 |
Why?
|
Tetrahydronaphthalenes | 1 | 2020 | 86 | 0.170 |
Why?
|
Infant, Newborn | 9 | 2024 | 26410 | 0.170 |
Why?
|
Biomedical Research | 3 | 2021 | 3464 | 0.170 |
Why?
|
Sequence Analysis, RNA | 4 | 2021 | 2038 | 0.170 |
Why?
|
Brain Neoplasms | 4 | 2023 | 9197 | 0.170 |
Why?
|
DEAD-box RNA Helicases | 2 | 2020 | 384 | 0.170 |
Why?
|
Treatment Outcome | 13 | 2024 | 65365 | 0.170 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 101 | 0.170 |
Why?
|
Myofibroma | 1 | 2019 | 45 | 0.160 |
Why?
|
Receptor, erbB-2 | 2 | 2024 | 2588 | 0.160 |
Why?
|
Quinolines | 1 | 2024 | 768 | 0.160 |
Why?
|
Chromosomes, Human, Pair 14 | 2 | 2017 | 286 | 0.160 |
Why?
|
Nomograms | 1 | 2020 | 236 | 0.160 |
Why?
|
Benzamides | 3 | 2023 | 1380 | 0.160 |
Why?
|
Valine | 1 | 2020 | 410 | 0.160 |
Why?
|
Carcinoma, Medullary | 1 | 2019 | 116 | 0.150 |
Why?
|
Kidney Neoplasms | 3 | 2021 | 4301 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2020 | 228 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2020 | 8628 | 0.150 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2019 | 5335 | 0.150 |
Why?
|
Ribonuclease III | 1 | 2020 | 270 | 0.150 |
Why?
|
Dystrophin | 1 | 2019 | 284 | 0.150 |
Why?
|
Nephroma, Mesoblastic | 1 | 2017 | 24 | 0.150 |
Why?
|
Epigenomics | 3 | 2019 | 959 | 0.150 |
Why?
|
Parotid Neoplasms | 1 | 2019 | 158 | 0.150 |
Why?
|
Neoplasm Metastasis | 6 | 2019 | 4921 | 0.150 |
Why?
|
Resource Allocation | 1 | 2020 | 354 | 0.150 |
Why?
|
Legislation, Drug | 1 | 2020 | 216 | 0.150 |
Why?
|
DNA Repair | 2 | 2024 | 2050 | 0.150 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2019 | 2950 | 0.140 |
Why?
|
Glioma | 2 | 2022 | 3526 | 0.140 |
Why?
|
Retrospective Studies | 17 | 2024 | 81768 | 0.140 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 550 | 0.140 |
Why?
|
Microtubule-Associated Proteins | 2 | 2022 | 1078 | 0.140 |
Why?
|
Benzimidazoles | 1 | 2022 | 864 | 0.140 |
Why?
|
Informed Consent | 1 | 2023 | 1010 | 0.130 |
Why?
|
Neuroblastoma | 1 | 2025 | 1265 | 0.130 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2017 | 117 | 0.130 |
Why?
|
von Hippel-Lindau Disease | 1 | 2017 | 154 | 0.130 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2024 | 2058 | 0.130 |
Why?
|
Karyopherins | 1 | 2016 | 134 | 0.130 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 342 | 0.130 |
Why?
|
Specimen Handling | 1 | 2020 | 707 | 0.130 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1141 | 0.120 |
Why?
|
Survival Rate | 5 | 2019 | 12870 | 0.120 |
Why?
|
SEER Program | 1 | 2020 | 1474 | 0.120 |
Why?
|
Genomic Imprinting | 1 | 2017 | 324 | 0.120 |
Why?
|
Pelvic Bones | 1 | 2017 | 274 | 0.120 |
Why?
|
Disease Models, Animal | 2 | 2014 | 18358 | 0.120 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2019 | 697 | 0.120 |
Why?
|
United States Food and Drug Administration | 3 | 2022 | 1672 | 0.120 |
Why?
|
RNA, Neoplasm | 1 | 2017 | 749 | 0.120 |
Why?
|
Pyridines | 2 | 2024 | 2889 | 0.120 |
Why?
|
Immunotherapy, Adoptive | 1 | 2024 | 1508 | 0.110 |
Why?
|
Pyrazines | 1 | 2019 | 1206 | 0.110 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2024 | 5711 | 0.110 |
Why?
|
Imidazoles | 1 | 2019 | 1168 | 0.110 |
Why?
|
United States | 15 | 2024 | 73144 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2016 | 594 | 0.110 |
Why?
|
Cell Line, Tumor | 7 | 2022 | 17132 | 0.110 |
Why?
|
Databases, Factual | 3 | 2023 | 8072 | 0.110 |
Why?
|
Follow-Up Studies | 8 | 2020 | 39405 | 0.100 |
Why?
|
Repressor Proteins | 2 | 2021 | 2986 | 0.100 |
Why?
|
Age Factors | 5 | 2024 | 18472 | 0.100 |
Why?
|
Prospective Studies | 10 | 2024 | 54921 | 0.100 |
Why?
|
Leukemia | 1 | 2021 | 1526 | 0.100 |
Why?
|
Poverty | 1 | 2024 | 2721 | 0.100 |
Why?
|
Cisplatin | 3 | 2019 | 1661 | 0.100 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2016 | 1339 | 0.100 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2019 | 1320 | 0.100 |
Why?
|
Serine Endopeptidases | 1 | 2017 | 1026 | 0.100 |
Why?
|
Age of Onset | 1 | 2019 | 3345 | 0.100 |
Why?
|
Patient Participation | 1 | 2021 | 1448 | 0.100 |
Why?
|
Glucocorticoids | 1 | 2021 | 2168 | 0.100 |
Why?
|
DNA Copy Number Variations | 2 | 2019 | 2046 | 0.100 |
Why?
|
Methotrexate | 3 | 2019 | 1722 | 0.100 |
Why?
|
Extremities | 1 | 2017 | 870 | 0.100 |
Why?
|
Gastrectomy | 1 | 2016 | 696 | 0.100 |
Why?
|
Combined Modality Therapy | 4 | 2022 | 8562 | 0.100 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 861 | 0.100 |
Why?
|
Cerebellar Neoplasms | 1 | 2016 | 590 | 0.090 |
Why?
|
Cell Survival | 1 | 2021 | 5792 | 0.090 |
Why?
|
Genetic Heterogeneity | 1 | 2014 | 737 | 0.090 |
Why?
|
Gene Dosage | 2 | 2017 | 1221 | 0.090 |
Why?
|
Medulloblastoma | 1 | 2016 | 682 | 0.090 |
Why?
|
Polyethylene Glycols | 1 | 2016 | 1195 | 0.090 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2013 | 393 | 0.090 |
Why?
|
Membrane Proteins | 3 | 2017 | 7885 | 0.090 |
Why?
|
Syndrome | 2 | 2021 | 3275 | 0.090 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3457 | 0.090 |
Why?
|
Antidotes | 1 | 2010 | 138 | 0.080 |
Why?
|
MicroRNAs | 2 | 2017 | 3794 | 0.080 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2021 | 2524 | 0.080 |
Why?
|
Biopsy | 4 | 2024 | 6808 | 0.080 |
Why?
|
DNA Damage | 3 | 2024 | 2459 | 0.080 |
Why?
|
Germ Cells | 2 | 2023 | 643 | 0.080 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2011 | 290 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinases | 2 | 2024 | 1246 | 0.080 |
Why?
|
Heart Neoplasms | 1 | 2012 | 374 | 0.080 |
Why?
|
Treatment Failure | 2 | 2017 | 2664 | 0.080 |
Why?
|
Mediastinal Neoplasms | 1 | 2011 | 403 | 0.070 |
Why?
|
Ecosystem | 2 | 2023 | 494 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2017 | 16027 | 0.070 |
Why?
|
Protein Subunits | 1 | 2010 | 943 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10776 | 0.070 |
Why?
|
Pedigree | 1 | 2014 | 4545 | 0.070 |
Why?
|
Translocation, Genetic | 2 | 2023 | 1395 | 0.070 |
Why?
|
Survivors | 2 | 2023 | 2382 | 0.070 |
Why?
|
Disease Progression | 5 | 2021 | 13646 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 13019 | 0.070 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2923 | 0.070 |
Why?
|
Oncogenes | 2 | 2022 | 1234 | 0.070 |
Why?
|
Thyroid Neoplasms | 1 | 2019 | 2360 | 0.070 |
Why?
|
Neurotoxicity Syndromes | 1 | 2010 | 302 | 0.060 |
Why?
|
Mice, Nude | 3 | 2019 | 3630 | 0.060 |
Why?
|
Immunohistochemistry | 3 | 2019 | 11117 | 0.060 |
Why?
|
Cyclin D | 1 | 2024 | 72 | 0.060 |
Why?
|
Chromosome Aberrations | 2 | 2025 | 1780 | 0.060 |
Why?
|
Immunotherapy | 2 | 2021 | 4740 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5705 | 0.060 |
Why?
|
Risk Assessment | 3 | 2020 | 24316 | 0.060 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2011 | 957 | 0.060 |
Why?
|
Forecasting | 1 | 2013 | 2948 | 0.060 |
Why?
|
Neoplasm Transplantation | 2 | 2019 | 2017 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 5443 | 0.060 |
Why?
|
Computer Simulation | 1 | 2017 | 6277 | 0.050 |
Why?
|
Clinical Protocols | 2 | 2022 | 1445 | 0.050 |
Why?
|
Gene Expression Profiling | 5 | 2017 | 9508 | 0.050 |
Why?
|
Infertility | 1 | 2010 | 655 | 0.050 |
Why?
|
Blotting, Western | 1 | 2010 | 5033 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2020 | 6404 | 0.050 |
Why?
|
Nuclear Proteins | 2 | 2023 | 5802 | 0.050 |
Why?
|
Cyclic AMP Response Element Modulator | 1 | 2023 | 88 | 0.050 |
Why?
|
Vidarabine | 1 | 2024 | 337 | 0.050 |
Why?
|
Hearing Loss | 1 | 2010 | 786 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2016 | 3921 | 0.050 |
Why?
|
Normetanephrine | 1 | 2021 | 25 | 0.050 |
Why?
|
Lymphocyte Depletion | 1 | 2024 | 605 | 0.050 |
Why?
|
Neoplasms, Second Primary | 1 | 2010 | 1060 | 0.050 |
Why?
|
Dogs | 2 | 2019 | 3846 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10863 | 0.050 |
Why?
|
Enzyme Activation | 1 | 2007 | 3585 | 0.050 |
Why?
|
3-Iodobenzylguanidine | 1 | 2022 | 115 | 0.050 |
Why?
|
Middle Aged | 14 | 2024 | 223463 | 0.050 |
Why?
|
Research Design | 2 | 2017 | 6209 | 0.050 |
Why?
|
Chromogranins | 1 | 2021 | 160 | 0.050 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2023 | 256 | 0.050 |
Why?
|
Trismus | 1 | 2020 | 33 | 0.050 |
Why?
|
Sacrum | 1 | 2022 | 275 | 0.040 |
Why?
|
DNA Methylation | 4 | 2017 | 4419 | 0.040 |
Why?
|
Survival Analysis | 3 | 2018 | 10117 | 0.040 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2020 | 33 | 0.040 |
Why?
|
Signal Transduction | 5 | 2021 | 23629 | 0.040 |
Why?
|
Oncogene Proteins | 2 | 2017 | 718 | 0.040 |
Why?
|
Aminopyridines | 1 | 2024 | 580 | 0.040 |
Why?
|
RNA-Binding Protein EWS | 1 | 2021 | 211 | 0.040 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2022 | 427 | 0.040 |
Why?
|
Oncogene Fusion | 1 | 2020 | 83 | 0.040 |
Why?
|
Cell Differentiation | 2 | 2023 | 11659 | 0.040 |
Why?
|
RNA | 2 | 2022 | 2726 | 0.040 |
Why?
|
Polymerase Chain Reaction | 1 | 2009 | 6084 | 0.040 |
Why?
|
Codon | 1 | 2021 | 599 | 0.040 |
Why?
|
Phosphorylation | 1 | 2010 | 8326 | 0.040 |
Why?
|
Mice | 6 | 2022 | 82004 | 0.040 |
Why?
|
Cell Cycle | 2 | 2019 | 2934 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 636 | 0.040 |
Why?
|
Receptor, Notch1 | 1 | 2022 | 520 | 0.040 |
Why?
|
Animals | 9 | 2022 | 169322 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2010 | 2103 | 0.040 |
Why?
|
Adrenal Glands | 1 | 2021 | 557 | 0.040 |
Why?
|
RNA Interference | 2 | 2019 | 2836 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2018 | 3616 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2014 | 10464 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 892 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2021 | 329 | 0.040 |
Why?
|
Workers' Compensation | 1 | 1999 | 150 | 0.040 |
Why?
|
Calcitonin | 1 | 2019 | 329 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 853 | 0.040 |
Why?
|
Carbazoles | 1 | 2019 | 221 | 0.040 |
Why?
|
Endothelial Cells | 1 | 2011 | 3587 | 0.040 |
Why?
|
Radionuclide Imaging | 1 | 2022 | 1998 | 0.040 |
Why?
|
Stem Cells | 1 | 2011 | 3537 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 12557 | 0.040 |
Why?
|
GTP-Binding Proteins | 1 | 2022 | 947 | 0.040 |
Why?
|
Cohort Studies | 5 | 2021 | 41791 | 0.040 |
Why?
|
Drug Labeling | 1 | 2020 | 250 | 0.040 |
Why?
|
Insulin-Like Growth Factor Binding Protein 2 | 1 | 2017 | 68 | 0.040 |
Why?
|
American Cancer Society | 1 | 2017 | 69 | 0.040 |
Why?
|
Utah | 1 | 2017 | 130 | 0.040 |
Why?
|
Breast Neoplasms | 2 | 2022 | 21163 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2024 | 1492 | 0.030 |
Why?
|
Heart Diseases | 1 | 2010 | 2819 | 0.030 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2017 | 178 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2018 | 4774 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2017 | 314 | 0.030 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2017 | 196 | 0.030 |
Why?
|
Risk Factors | 5 | 2025 | 74954 | 0.030 |
Why?
|
Necrosis | 1 | 2020 | 1619 | 0.030 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2017 | 303 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2017 | 474 | 0.030 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2017 | 252 | 0.030 |
Why?
|
Safety | 1 | 2020 | 1159 | 0.030 |
Why?
|
Aged | 8 | 2024 | 171544 | 0.030 |
Why?
|
Carpal Tunnel Syndrome | 1 | 1999 | 304 | 0.030 |
Why?
|
Exons | 1 | 2021 | 2392 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2518 | 0.030 |
Why?
|
T-Lymphocytes | 2 | 2024 | 10266 | 0.030 |
Why?
|
Consensus | 1 | 2024 | 3212 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7453 | 0.030 |
Why?
|
Hydrazines | 1 | 2016 | 223 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 620 | 0.030 |
Why?
|
Drug Synergism | 1 | 2018 | 1760 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2017 | 753 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2019 | 1794 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 1765 | 0.030 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2017 | 462 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2019 | 1337 | 0.030 |
Why?
|
Ubiquitin | 1 | 2019 | 843 | 0.030 |
Why?
|
Data Collection | 1 | 2023 | 3324 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2016 | 720 | 0.030 |
Why?
|
Computational Biology | 2 | 2017 | 3541 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2022 | 2056 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2016 | 794 | 0.030 |
Why?
|
Small Molecule Libraries | 1 | 2018 | 743 | 0.030 |
Why?
|
Motivation | 1 | 2023 | 2029 | 0.030 |
Why?
|
Chromatin | 1 | 2025 | 2967 | 0.030 |
Why?
|
Models, Biological | 2 | 2021 | 9494 | 0.030 |
Why?
|
Drug Approval | 1 | 2020 | 818 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2021 | 59683 | 0.030 |
Why?
|
Early Detection of Cancer | 2 | 2017 | 3236 | 0.030 |
Why?
|
Europe | 1 | 2019 | 3439 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2022 | 1902 | 0.030 |
Why?
|
Pneumonectomy | 1 | 2019 | 1158 | 0.030 |
Why?
|
Neoplasm Proteins | 2 | 2017 | 3609 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2022 | 2734 | 0.020 |
Why?
|
Self Efficacy | 1 | 2016 | 643 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2022 | 2811 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1748 | 0.020 |
Why?
|
Base Sequence | 1 | 2022 | 12421 | 0.020 |
Why?
|
Regression Analysis | 1 | 2020 | 6350 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2014 | 1705 | 0.020 |
Why?
|
Piperidines | 1 | 2019 | 1660 | 0.020 |
Why?
|
Triazoles | 1 | 2016 | 904 | 0.020 |
Why?
|
Sex Factors | 1 | 2025 | 10656 | 0.020 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2012 | 193 | 0.020 |
Why?
|
Quality of Life | 2 | 2022 | 13499 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 2924 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2015 | 1064 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2021 | 20224 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3622 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3631 | 0.020 |
Why?
|
Genomic Instability | 1 | 2013 | 715 | 0.020 |
Why?
|
Acetylation | 1 | 2011 | 1053 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2011 | 482 | 0.020 |
Why?
|
Time Factors | 2 | 2020 | 40267 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6892 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3826 | 0.020 |
Why?
|
Health Policy | 1 | 2020 | 2698 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2016 | 3553 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2024 | 9618 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 1608 | 0.020 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 623 | 0.020 |
Why?
|
Prevalence | 1 | 2023 | 15868 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2016 | 2337 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 2727 | 0.020 |
Why?
|
Carcinoma | 1 | 2017 | 2340 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6541 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2011 | 775 | 0.020 |
Why?
|
Bone Marrow | 1 | 2016 | 2929 | 0.020 |
Why?
|
Proteomics | 1 | 2019 | 3906 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2022 | 6670 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 5800 | 0.010 |
Why?
|
Research | 1 | 2012 | 1981 | 0.010 |
Why?
|
Boston | 1 | 2017 | 9371 | 0.010 |
Why?
|
Transcription Factors | 1 | 2023 | 12166 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7063 | 0.010 |
Why?
|
Recurrence | 1 | 2016 | 8501 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7599 | 0.010 |
Why?
|
Transfection | 1 | 2011 | 5758 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2394 | 0.010 |
Why?
|
Parents | 1 | 2016 | 3596 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3436 | 0.010 |
Why?
|
Histones | 1 | 2011 | 2593 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2011 | 5898 | 0.010 |
Why?
|
Antigens, CD | 1 | 2011 | 4031 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 36849 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20766 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2013 | 12801 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 10377 | 0.010 |
Why?
|
New York | 1 | 1999 | 884 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 13038 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2011 | 4069 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 26373 | 0.010 |
Why?
|
Insurance Claim Review | 1 | 1999 | 746 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2011 | 22292 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 1999 | 7861 | 0.000 |
Why?
|
Logistic Models | 1 | 1999 | 13323 | 0.000 |
Why?
|
Health Services Accessibility | 1 | 1999 | 5511 | 0.000 |
Why?
|